ro7496353

RO7496353 is an investigational monoclonal antibody that selectively targets and inhibits the activation of latent transforming growth factor beta 1 (TGF-β1). By blocking TGF-β1 activation, it aims to counteract the immunosuppressive tumor microenvironment, thereby enhancing anti-tumor immune responses. This mechanism is particularly relevant in combination with checkpoint inhibitors for cancer therapy. Preclinical studies have shown that RO7496353 can modulate the tumor microenvironment and synergize with anti-PD-L1 therapies, leading to improved anti-tumor efficacy. The drug is currently in Phase 1 clinical trials for various advanced solid tumors, including non-small cell lung cancer (NSCLC), gastric cancer (GC), and pancreatic ductal adenocarcinoma (PDAC). Early clinical data indicate a need for careful safety monitoring due to observed liver-related dose-limiting toxicity[2][4][5].

Other names

anti-latent TGFb1 monoclonal antibody RO7496353